Recent Development News: Q1 – 2018

Cerecor Appoints Peter Greenleaf as Chief Executive Officer

BALTIMORE, MD — (Marketwired) — 03/28/18 — Cerecor, Inc. (NASDAQ: CERC) today announced that its Board of Directors has appointed Peter Greenleaf as Chief Executive Officer. Mr. Greenleaf has served on the Company’s board since May 2017. He brings to … Continue reading

Posted in Recent Development News: Q1 - 2018, Recent Developments | Comments Off

ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

YONKERS, N.Y., March 15, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for the fourth quarter and full … Continue reading

Posted in Recent Development News: Q1 - 2018, Recent Developments | Comments Off

Centrexion Therapeutics to Present CNTX-4975 Clinical Data at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting

BOSTON, Mass., March 1, 2018 – Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced it will present Phase 2b data of CNTX-4975 for the treatment of moderate to severe … Continue reading

Posted in Recent Development News: Q1 - 2018, Recent Developments | Comments Off

Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain

BOSTON, Mass., February 21, 2018 – Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that the first patient has been dosed in its Phase 3 VICTORY-1 clinical trial of … Continue reading

Posted in Recent Development News: Q1 - 2018, Recent Developments | Comments Off

Cerecor to Acquire Avadel Pharmaceuticals’ Pediatric Assets

BALTIMORE, MD — (Marketwired) — 02/12/18 — Cerecor, Inc.(NASDAQ: CERC) today announced it has entered into definitive agreements with Avadel U.S. Holdings, Inc., and certain of its subsidiaries, to purchase and acquire all rights to Avadel’s marketed pediatric products. The … Continue reading

Posted in Recent Development News: Q1 - 2018, Recent Developments | Comments Off

Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain

BOSTON, Mass., January 16, 2018 – Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CNTX-4975 … Continue reading

Posted in Recent Development News: Q1 - 2018, Recent Developments | Comments Off

Centrexion Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

BOSTON, Mass., January 5, 2018 – Centrexion Therapeutics, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that Jeffrey B. Kindler, chief executive officer, will present at 3:00 p.m. PT on Tuesday, January … Continue reading

Posted in Recent Development News: Q1 - 2018, Recent Developments | Comments Off

Centrexion Therapeutics Raises $67 Million; Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018

BOSTON, Mass., January 2, 2018 – Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced the successful completion of a $67 million Series D financing.

Posted in Recent Development News: Q1 - 2018, Recent Developments | Comments Off